Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types |
| |
| Authors: | Giosuè Scognamiglio Anna De Chiara Maurizio Di Bonito Fabiana Tatangelo Nunzia Simona Losito Annamaria Anniciello Rossella De Cecio Crescenzo D’Alterio Stefania Scala Monica Cantile Gerardo Botti |
| |
| Affiliation: | 1Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, via Mariano Semmola, 80131 Napoli, Italy; (G.S.); (A.D.C.); (M.D.B.); (F.T.); (N.S.L.); (A.A.); (R.D.C.); (G.B.);2Molecular Immunology and Immunoregulation Functional Genomics, Istituto Nazionale Tumori Fondazione “G. Pascale”, via Mariano Semmola, 80131 Napoli, Italy; (C.D.); (S.S.) |
| |
| Abstract: | In normal cell physiology, programmed death 1 (PD-1) and its ligand, PD-L1, play an immunoregulatory role in T-cell activation, tolerance, and immune-mediated tissue damage. The PD-1/PD-L1 pathway also plays a critical role in immune escape of tumor cells and has been demonstrated to correlate with a poor prognosis of patients with several types of cancer. However, recent reports have revealed that the immunohistochemical (IHC) expression of the PD-L1 in tumor cells is not uniform for the use of different antibodies clones, with variable specificity, often doubtful topographical localization, and with a score not uniquely defined. The purpose of this study was to analyze the IHC expression of PD-L1 on a large series of several human tumors to correctly define its staining in different tumor tissues. |
| |
| Keywords: | PD-L1, immunohistochemical staining, tissue type’ s variability |
|
|
